Published in Mol Cell Biol on December 04, 2006
Control of mammary stem cell function by steroid hormone signalling. Nature (2010) 5.38
RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature (2010) 3.66
Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nat Rev Cancer (2013) 2.60
Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci U S A (2010) 2.45
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov (2012) 2.07
Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis (2007) 1.42
Osteoimmunology: crosstalk between the immune and bone systems. J Clin Immunol (2009) 1.39
Mammary involution and breast cancer risk: transgenic models and clinical studies. J Mammary Gland Biol Neoplasia (2009) 1.32
The NFκB pathway: a therapeutic target in glioblastoma. Oncotarget (2011) 1.25
The biology of progesterone receptor in the normal mammary gland and in breast cancer. Mol Cell Endocrinol (2011) 1.19
Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity. Autophagy (2014) 1.14
Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines. J Exp Clin Cancer Res (2013) 1.08
Progestin-regulated luminal cell and myoepithelial cell-specific responses in mammary organoid culture. Endocrinology (2008) 1.05
Progesterone receptor isoform functions in normal breast development and breast cancer. Crit Rev Eukaryot Gene Expr (2008) 0.97
From the ranks of mammary progesterone mediators, RANKL takes the spotlight. Mol Cell Endocrinol (2011) 0.94
Signal transducer and activator of transcription 5a mediates mammary ductal branching and proliferation in the nulliparous mouse. Endocrinology (2010) 0.92
RANK expression on breast cancer cells promotes skeletal metastasis. Clin Exp Metastasis (2013) 0.91
Pubertal high fat diet: effects on mammary cancer development. Breast Cancer Res (2013) 0.87
Progestin effects on cell proliferation pathways in the postmenopausal mammary gland. Breast Cancer Res (2013) 0.87
Stem cells: Cues from steroid hormones. Nature (2010) 0.83
Identification of novel human receptor activator of nuclear factor-kB isoforms generated through alternative splicing: implications in breast cancer cell survival and migration. Breast Cancer Res (2012) 0.83
TNFRSF11A and TNFSF11 are associated with age at menarche and natural menopause in white women. Menopause (2010) 0.83
Association of cellular and molecular responses in the rat mammary gland to 17β-estradiol with susceptibility to mammary cancer. BMC Cancer (2013) 0.82
Cellular microenvironment influences the ability of mammary epithelia to undergo cell cycle. PLoS One (2011) 0.79
Role of RANKL/RANK in primary and secondary breast cancer. World J Orthop (2013) 0.79
Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women. Front Oncol (2016) 0.76
Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences. J Bone Oncol (2012) 0.76
A local basis for progesterone action during mammary tumorigenesis - no longer RANK and file. Breast Cancer Res (2011) 0.75
Antibody-mediated "universal" osteoclast targeting platform using calcitonin as a model drug. Pharm Res (2011) 0.75
Impact of denosumab on bone mass in cancer patients. Clin Pharmacol (2013) 0.75
Aberrant Activation of the RANK Signaling Receptor Induces Murine Salivary Gland Tumors. PLoS One (2015) 0.75
The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma. Oncotarget (2017) 0.75
RANK-RANKL signalling in cancer. Biosci Rep (2016) 0.75
Loss of Glutaredoxin 3 Impedes Mammary Lobuloalveolar Development during Pregnancy and Lactation. Am J Physiol Endocrinol Metab (2016) 0.75
Estrogen receptors in breast and bone: from virtue of remodeling to vileness of metastasis. Oncogene (2017) 0.75
Circulating RANKL and RANKL/OPG and breast cancer risk by ER and PR subtype: Results from the EPIC cohort. Cancer Prev Res (Phila) (2017) 0.75
Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods (2003) 18.51
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell (1998) 17.76
NF-kappaB at the crossroads of life and death. Nat Immunol (2002) 12.98
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (1999) 12.32
Mechanisms of bone metastasis. N Engl J Med (2004) 10.40
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature (1997) 8.59
Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A (1992) 8.59
Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell (1988) 7.50
The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell (2002) 7.35
Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell (1984) 6.71
ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat Cell Biol (2001) 6.21
RANK is essential for osteoclast and lymph node development. Genes Dev (1999) 5.85
Functional differentiation and alveolar morphogenesis of primary mammary cultures on reconstituted basement membrane. Development (1989) 5.62
Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell (1987) 5.57
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature (1994) 5.34
Regulation of cancer cell migration and bone metastasis by RANKL. Nature (2006) 5.27
Maintenance and induction of morphological differentiation in dissociated mammary epithelium on floating collagen membranes. In Vitro (1977) 4.69
The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell (2000) 4.53
Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol Cell Biol (2004) 4.45
Modulation of secreted proteins of mouse mammary epithelial cells by the collagenous substrata. J Cell Biol (1984) 3.16
IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell (2001) 3.10
Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med (1999) 3.07
The macrophage growth factor CSF-1 in mammary gland development and tumor progression. J Mammary Gland Biol Neoplasia (2002) 2.37
NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci U S A (2004) 2.33
Bim regulation of lumen formation in cultured mammary epithelial acini is targeted by oncogenes. Mol Cell Biol (2005) 2.20
Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology (1999) 2.11
Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. Am J Pathol (2000) 1.99
Expression of a truncated Int3 gene in developing secretory mammary epithelium specifically retards lobular differentiation resulting in tumorigenesis. Cancer Res (1996) 1.90
The genetic transformation of bone biology. Genes Dev (1999) 1.80
Receptor activator of NF-kappaB ligand regulates the proliferation of mammary epithelial cells via Id2. Mol Cell Biol (2006) 1.67
Hepatocyte-specific inhibition of NF-kappaB leads to apoptosis after TNF treatment, but not after partial hepatectomy. J Clin Invest (2002) 1.58
Autocrine CSF-1R activation promotes Src-dependent disruption of mammary epithelial architecture. J Cell Biol (2004) 1.56
NF-kappaB in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia (2003) 1.47
Receptor activator of NF-kappaB ligand induction via Jak2 and Stat5a in mammary epithelial cells. J Biol Chem (2003) 1.43
Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors. Mol Cell Biol (2003) 1.36
Ha-ras and c-myc oncogene expression interferes with morphological and functional differentiation of mammary epithelial cells in single and double transgenic mice. Genes Dev (1988) 1.35
RelB/p52 NF-kappaB complexes rescue an early delay in mammary gland development in transgenic mice with targeted superrepressor IkappaB-alpha expression and promote carcinogenesis of the mammary gland. Mol Cell Biol (2005) 1.32
Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression. J Biol Chem (2003) 1.21
Dynamic expression and activity of NF-kappaB during post-natal mammary gland morphogenesis. Mech Dev (2000) 1.21
Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res (2001) 1.13
Mouse models for breast cancer. Breast Cancer Res (1999) 1.00
Overexpression of the colony-stimulating factor (CSF-1) and/or its receptor c-fms in mammary glands of transgenic mice results in hyperplasia and tumor formation. Cancer Res (2004) 0.98
The hematopoietic transcription factor PU.1 regulates RANK gene expression in myeloid progenitors. Biochem Biophys Res Commun (2005) 0.91
Common mechanisms of osteosarcoma and Paget's disease. J Bone Miner Res (1999) 0.87
Over-expression of erbB-2/neu is paralleled by inhibition of mouse-mammary-epithelial-cell differentiation and developmental apoptosis. Int J Cancer (2000) 0.87
Prostate carcinoma: production of bioactive factors. Cancer (2000) 0.84
Apoptosis and involution in the mammary gland are altered in mice lacking a novel receptor, beta1,4-Galactosyltransferase I. Dev Biol (2004) 0.79
Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. N Engl J Med (2010) 13.57
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
The DNA sequence of the human X chromosome. Nature (2005) 6.97
The genome of the model beetle and pest Tribolium castaneum. Nature (2008) 6.50
The genome of the sea urchin Strongylocentrotus purpuratus. Science (2006) 6.41
RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature (2010) 3.66
Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J Exp Med (2007) 2.59
Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res (2009) 2.51
Rare complete knockouts in humans: population distribution and significant role in autism spectrum disorders. Neuron (2013) 2.45
IL-36R ligands are potent regulators of dendritic and T cells. Blood (2011) 2.20
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov (2012) 2.07
RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis. Cancer Res (2012) 1.98
IL-1 family nomenclature. Nat Immunol (2010) 1.79
Paradoxical DNA repair and peroxide resistance gene conservation in Bacillus pumilus SAFR-032. PLoS One (2007) 1.71
A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer Res (2012) 1.70
Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J Clin Invest (2012) 1.58
Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res (2010) 1.56
A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J Biol Chem (2002) 1.54
Analysis of rare, exonic variation amongst subjects with autism spectrum disorders and population controls. PLoS Genet (2013) 1.53
Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis. Cancer Biol Ther (2010) 1.53
RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate (2008) 1.42
Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis (2007) 1.42
IL-1RL2 and its ligands contribute to the cytokine network in psoriasis. J Immunol (2010) 1.40
Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth. Cancer Res (2011) 1.38
Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha. J Biol Chem (2004) 1.30
Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging. Mol Cancer Ther (2007) 1.28
Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration. J Bone Miner Res (2006) 1.18
Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone. Bone (2008) 1.18
In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. J Bone Miner Res (2002) 1.17
RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol Cancer Ther (2008) 1.13
Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing. J Orthop Res (2003) 1.10
RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev (2007) 1.08
The chaperone-like protein HYPK acts together with NatA in cotranslational N-terminal acetylation and prevention of Huntingtin aggregation. Mol Cell Biol (2010) 1.07
The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone. J Orthop Res (2005) 1.04
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor. J Med Chem (2013) 1.00
RIP4 regulates epidermal differentiation and cutaneous inflammation. J Invest Dermatol (2010) 1.00
RANK expression as a prognostic and predictive marker in breast cancer. Breast Cancer Res Treat (2014) 0.93
Strategies to design and analyze targeted sequencing data: cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium Targeted Sequencing Study. Circ Cardiovasc Genet (2014) 0.93
RANK expression on breast cancer cells promotes skeletal metastasis. Clin Exp Metastasis (2013) 0.91
RANKL inhibition: from mice to men (and women). Adv Exp Med Biol (2007) 0.90
Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection. J Immunol (2007) 0.87
Progestin effects on cell proliferation pathways in the postmenopausal mammary gland. Breast Cancer Res (2013) 0.87
Constitutive activation of RANK disrupts mammary cell fate leading to tumorigenesis. Stem Cells (2013) 0.85
Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis. Bone (2010) 0.84
RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model. Breast Cancer Res Treat (2012) 0.83
Effects of the RANKL inhibitor, osteoprotegerin, on the pain and histopathology of bone cancer in rats. Clin Exp Metastasis (2006) 0.83
RANKL expression in normal and malignant breast tissue responds to progesterone and is up-regulated during the luteal phase. Breast Cancer Res Treat (2014) 0.82
The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction. Ann N Y Acad Sci (2012) 0.82
RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. Breast Cancer Res (2015) 0.81
RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases. J Thorac Oncol (2014) 0.81
Combined inhibition of the BMP pathway and the RANK-RANKL axis in a mixed lytic/blastic prostate cancer lesion. Bone (2010) 0.80
Distribution of RANK and RANK Ligand in Normal Human Tissues as Determined by an Optimized Immunohistochemical Method. Appl Immunohistochem Mol Morphol (2017) 0.75
A modular zinc finger adaptor accelerates the covalent linkage of proteins at specific locations on DNA nanoscaffolds. Chem Commun (Camb) (2015) 0.75